Antithrombotic therapy and venous graft disease

Current Opinion in Cardiology

Volumn 13, Issue 6, 1998, Pages 459-464

  Schussheim, Adam E ^a   Fuster, Valentin ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; DIPYRIDAMOLE; FIBRINOGEN; INDOBUFEN; LIPOPROTEIN A; MEVINOLIN; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; GRAFT OCCLUSION; HUMAN; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; VEIN DISEASE; VEIN GRAFT; VEIN THROMBOSIS;

EID: 0031786584     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199811000-00012     Document Type: Review

References (43)

1. Willman VL: Aortocoronary bypass with saphenous vein graft. JAMA 1996, 276:1521-1525.
2. Motwani JG, Topo EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97:916-931.
3. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR: Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996, 28:616-626.
4. Fuster V, Chesebro JH: Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation 1986, 73:227-232.
5. Bryan AJ, Angelini GD: Vascular biology of coronary artery bypass conduits: new solutions to old problems. Adv Card Surg 1996, 8:47-80.
6. Allaire E, Clowes AW: Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg 1997, 63:582-591. This informative review examines the pivotal role of endothelial dysfunction in initiating and perpetuating graft disease.
7. Cox JL, Chiasson DA, Gotlieb AI: Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991, 34:886-894.
8. Angelini GD, Brechenridge IM, Psaila JV, Williams HM, Henderson AH, Newby AC: Preparation of human saphenous vein for coronary artery bypass grafting impairs its capacity to produce prostacyclin. Cardiovasc Res 1987, 21:28-33.
9. Angelini GD, Christie MI, Bryan AJ, Lewis MJ: Surgical preparation impairs release of endothelium-derived relaxing factor from human saphenous vein. Ann Thorac Surg 1989, 48:417-20.
10. Nwasokwa ON: Coronary artery bypass graft disease. Ann Intern Med 1995, 123:528-545.
11. Verrier ED, Boyle EM: Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 1996, 62:915-922.
12. Cook JM, Cook CD, Marlar R, Solis MM, Fink L, Eidt JF: Thrombomodulin activity in human saphenous vein grafts prepared for coronary artery bypass. J Vasc Surg 1991, 14:147-151.
13. Moggio RA, Ding JZ, Smith CJ, Tota RR, Stemeerman MB, Reed GE: Immediate-early gene expression in human saphenous veins harvested during coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1995, 110:209-213.
14. Kohler T, Kirkman TR, Clowes AW: The effect of rigid external support on vein graft adaptation to arterial circulation. J Vasc Surg 1989, 3:877-884.
15. Gallo R, Padurean A, Toschi V, et al.: Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998, 97:581-588.
16. Ratliff NB, Myles JL: Rapidly progressive atherosclerosis in aortocoronary bypass vein grafts: possible immune-mediated disease. Arch Pathol Lab Med 1989, 113:772-776.
17. Solymoss BC, Nadeau P, Millette D, Campeau L: Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988, 78(suppl I):I-140-I-143.
18. Nishioka T, Luo H, Beglund H, et al.: Absence of focal compensatory enlargement or constriction in diseased human coronary saphenous vein bypass grafts: an intravascular ultrasound study. Circulation 1996, 93:683-690.
19. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1317-1375.
20. Silva JA, White CJ, Collins TJ, Ramee SR: Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. Am Heart J 1998, 136:156-163.
21. Skinner JS, Farrer M, ALbers CJ, Piper K, Neil HAW, Adams PC: Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart 1997, 78:131-135.
22. Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H: Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995, 79:223-226.
23. Rifon J, Paramo JA, Panizo C, Montes R, Rocha E: The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorta-coronary bypass surgery. Br J Haematol 1997, 99:262-267.
24. Hicks RCJ, Golledge J, Mir-Hasseine R, Powerll JT: Vasoactive effects of fibrinogen on saphenous vein. Nature 1996, 379:818-820.
25. Hicks RC, Ellis M, Mir-Hasseine R, Higman DJ, Nort D, Greenhalgh RM: The influence of fibrinogen concentration on the development of vein graft stenoses. Eur J Vasc Surg 1995, 9:415-420.
26. Channon KM, Fulton GJ, Davies MG, et al.: Modulation of tissue factor protein expression in experimental venous bypass grafts. Arterioscler Thromb Vasc Biol 1997, 17:1313-1319.
27. Stein PD, Dalen JE, Goldman S, Schwartz L, Theroux P, Turpie AGG: Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 1995, 108:4245-4303.
28. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T: Long-term graft patency (3 years) after coronary artery surgery: effects of aspirin: results of a VA Cooperative Study. Circulation 1994, 89:1138-1143.
29. Chesebro JH, Clements IP, Fuster V, et al.: A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982, 307:73-78.
30. Goldman S, Copeland J, Moritz T, et al.: Starting aspirin therapy after operation: effects on early graft patency. Circulation 1991, 84:520-526.
31. van der Meer J, Hillege HL, Kootstra GJ, et al.: Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 1993, 342:257-264.
32. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB: High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992, 85:1077-1082.
33. Limet R, David JL, Magotteaux P, Larock MP, Rigo P: Prevention of aortacoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987, 94:773-783.
34. SINBA Group (Studio Indobufene nel Bypas Aortocoronarico): Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coron Artery Dis 1991, 2:897-905.
35. Rajah SM, Nair U, Rees M, Saunders N, Walker D, Williams G: Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994, 107:1146-1153.
36. Cataldo G, Heiman F, Lavezzari M, Marubini E: Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis. Coron Artery Dis 1998, 9:217-222.
37. Weber MAJ, Hasford J, Taillens C, et al.: Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 1989, 2:1-7.
38. Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997, 336:153-162. This two-by-two randomized controlled trial demonstrated that aggressive cholesterol reduction (LDL < 100) reduced by almost 30% the progression of atherosclerosis and the need for revascularization procedures among patients who had undergone CABG. Low-dose warfarin (Coumadin) anticoagulation did not provide any detectable clinical benefit in this study of 1351 patients with average follow-up of 4.3 years.
39. Komiyama N, Nakanishi S, Nishiyama S, Seki A: Intravascular imaging of serial changes of disease in saphenous vein grafts after coronary artery bypass grafting. Am Heart J 1996, 132:30-40.
40. Chen L, Theroux P, Lesperance J, Shabani F, Thibault B, de Guise P: Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996, 28:1493-1499.
41. Fuster V, Vorchheimer DA: Prevention of atherosclerosis in coronary-artery bypass grafts. N Engl J Med 1997, 336:212-213.
42. AHJ at the Meeting. American Heart J 1998:1105-1110.
43. Medical Research Council's General Practice Research Framework: Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998, 351:233-241.